1. C1q potentiates DR5 agonist activity by a mixture of two DR5-specific HexaBody® molecules. (October 2018) Authors: Beurskens, Frank; Overdijk, Marije; Strumane, Kristin; Buijsse, Antonio Ortiz; Vermot-Desroches, Claudine; Kroes, Thessa; de Jong, Bart; Hoevenaars, Naomi; de Jong, Rob; Lingnau, Andreas; Parren, Paul; Schuurman, Janine; Breij, Esther Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of an Experimental Gonococcal Lipooligosaccharide Mimitope Vaccine Requires Terminal Complement. (31st December 2021) Authors: Lewis, Lisa A; Gulati, Sunita; Zelek, Wioleta M; Morgan, B Paul; Song, Wen-Chao; Zheng, Bo; Nowak, Nancy; DeOliveira, Rosane B; Sanchez, Bryan; DeSouza Silva, Leandro; Schuurman, Janine; Beurskens, Frank; Ram, Sanjay; Rice, Peter A Journal: Journal of infectious diseases Issue: Volume 225:Number 10(2022) Page Start: 1861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency. (October 2018) Authors: Taylor, Ronald; Lindorfer, Margaret; Oostindie, Simone; Cook, Erika; Zent, Clive; Burack, Richard; Beurskens, Frank; Schuurman, Janine; Breij, Esther; Parren, Paul Journal: Molecular immunology Issue: Volume 102(2018:Oct.) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗